|
| Evidence mapping of clinical research on Chinese patent medicines for post-stroke depression |
| Hits 347 Download times 190 Received:May 08, 2025 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2025.09.11 |
| Key Words
Chinese patent medicine;post-stroke depression;randomized controlled trial;evidence mapping;systematic review |
| Author Name | Affiliation | E-mail | | WANG Xiaolin | Department of Encephalopathy, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, China
The First Clinical Medical College of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, China | | | JI Zhaochen | Center of Evidence-Based Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | WANG Xiaoyan | Department of Encephalopathy, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, China | | | SHI Menglong | Center of Evidence-Based Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | LI Zhaoji | Department of Encephalopathy, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, China
The First Clinical Medical College of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, China | | | ZHAO Hanxiao | Department of Encephalopathy, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, China
The First Clinical Medical College of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, China | | | ZHANG Chidao | The First Clinical Medical College of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, China | | | ZHAO Min | Department of Encephalopathy, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, China | byts1969@126.com |
|
| Abstract
|
| [Objective] In this study，evidence mapping was employed to systematically sort out the evidence from clinical studies of Chinese patent medicines for post-stroke depression evaluate the current situation of Chinese patent medicine in the treatment of post-stroke depression，understand the current situation of evidence distribution in this field，and provide reference for the development of follow-up clinical research，guidelines and consensus formulation. [Methods] CNKI，VIP，Wanfang Database，SinoMed，PubMed，EMbase and Cochrane Library databases were systematically searched to collect randomized controlled trials（RCTs），systematic reviews/Meta-analysises，and guidelines/consensus of Chinese patent medicine in the treatment of post-stroke depression in recent years. The Cochrane bias assessment tool，AMSTAR-2 and AGREE Ⅱ were used to evaluate the quality，and the distribution characteristics were displayed and analyzed by text description combined with charts，bubble charts，pie charts and histograms. [Results] A total of 225 RCTs， 11 systematic reviews/Meta-analysis，2 network Meta-analysis，and 7 guidelines/consensus were included. [Conclusion] In recent years，the research on the treatment of post-stroke depression with Chinese patent medicine has shown an increasing trend. There are many kinds of Chinese patent medicine，but the quality of the literature is generally low. Most of the RCTs are small sample，single center and short course of treatment. In terms of the selection of outcome indicators，the outcome indicators have not been standardized and unified. The evaluation of neurological deficits，mental psychology，daily living ability，clinical efficiency and biological markers of neurological diseases are the main ones，and the characteristic advantages of traditional Chinese medicine are not clear. The overall quality of systematic review/Meta-analysis is low，and there is a lack of evidence for the efficacy of Chinese patent medicines in the treatment of post-stroke depression. The results showed that there were some advantages in the efficacy and safety of Chinese patent medicine in the treatment of post-stroke depression，but there was a lack of high-quality evidence-based evidence to provide support. Future research should pay attention to solving the above problems，standardize the relevant systematic review/Meta-analysis，guidelines/consensus-making process，improve the quality of clinical research，and carry out comprehensive clinical evaluation，so as to provide a more sound scientific basis for the treatment of post-stroke depression with Chinese patent medicine. |
|
|
|
|
|
|
|
